231 Sheep LLC

231 Sheep LLC is a minority-owned, self-certified small disadvantaged business located in San Gabriel, California, specializing in developing innovative healthcare technology solutions focused on medication adherence and remote monitoring. The company appears to concentrate on advanced medical technologies, particularly in ophthalmological care, with a specific emphasis on developing remote medication tracking and management systems for patients with eye-related conditions. As a corporate entity registered in SAM.gov with a current registration valid through February 2025, the company is structured as a for-profit limited liability company with multiple business designations including Asian-Pacific American owned.

The federal contract awards for 231 Sheep LLC have been exclusively with the Air Force Research Laboratory, both under the Small Business Innovation Research (SBIR) Program. The company has received two prime contract awards focusing on a Remote Eye Drop Medication Adherence Solution, with contracts designated as total small business set-asides. The first contract (FA864922P0277), awarded in November 2021 for $49,984, was a Phase I SBIR action for developing a remote medication adherence solution for glaucoma patients. The subsequent contract (FA864922P1056), awarded in July 2022 for $749,929, was a Phase II SBIR purchase order to deliver the OCUELAR Remote Eye Drop Medication Adherence Solution, with a performance period extending through May 2024.

The federal grant award for 231 Sheep LLC comes from the National Institute on Aging (NIA), a civilian agency, and represents a $301,941 Project Grant under the Aging Research program. The grant, awarded on September 1, 2024, supports the development of the OCUELAR system with a specific focus on revolutionizing glaucoma management in medically underserved communities. The grant project is scheduled to be completed by August 31, 2025, and aims to improve accessibility and quality of glaucoma care for populations with limited access to specialized ophthalmology services. This grant award aligns with the company's previous contract work, demonstrating a consistent commitment to developing innovative healthcare technologies that address critical medical monitoring and treatment challenges.